EPHA3 and malignant colon neoplasm: To investigate this possibility, we overexpressed mutant EPHA3D806N in DLD1 and LS174T colon cancer cells with low endogenous EPHA3 expression, or used a CRISPR/Cas9 strategy to knockout the mutant EPHA3 expressed at high levels in SW48 cells.